Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

13.87USD
4:00pm EDT
Change (% chg)

$0.72 (+5.48%)
Prev Close
$13.15
Open
$13.04
Day's High
$13.99
Day's Low
$13.00
Volume
779,276
Avg. Vol
722,899
52-wk High
$22.38
52-wk Low
$3.01

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $1,210.32
Shares Outstanding(Mil.): 88.02
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -0.67 -- --
ROI: -53.98 1.96 12.83
ROE: -56.57 1.12 14.95

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

Oct 04 2018

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

Oct 04 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Oct 4 Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

Oct 04 2018

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

May 11 2018

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

May 08 2018

Earnings vs. Estimates